Area of research
Hepatology · Epidemiology
Research interest
Research interests include Liver Disease Diagnosis and Treatment, Liver physiology and pathology, Liver Disease and Transplantation, and Kruppel-like factors research.
Anti-FAP CAR T cells produced in vivo reduce fibrosis and restore liver homeostasis in metabolic dysfunction-associated steatohepatitis.
Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease (<scp>MASLD</scp>) and Metabolic Dysfunction‐Associated Steatohepatitis (<scp>MASH</scp>): From the Growing Prevalence to Payors' Perspective
Hot and cold fibrosis: The role of serum biomarkers to assess immune mechanisms and ECM-cell interactions in human fibrosis
Aramchol improves hepatic fibrosis in metabolic dysfunction-associated steatohepatitis: Results of multimodality assessment using both conventional and digital pathology.
Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics
ACLY inhibition promotes tumour immunity and suppresses liver cancer.
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease.
Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics.
In vivo anti-FAP CAR T therapy reduces fibrosis and restores liver homeostasis in metabolic dysfunction-associated steatohepatitis
Chimeric antigen receptor (CAR) T-cell therapy: Engineering immune cells to treat liver diseases.
Endothelial-to-mesenchymal transition: A targetable mechanism that contributes to portal vein thrombosis in cirrhosis.
Can we talk? The cryptic communications of hepatic stellate cells in lipid metabolism.
Depletion of tumor-reactive HSCs reveals their significance during different stages of liver metastasis.
Resolvin D1-mediated cellular crosstalk protects against MASH.
Mannose reduces fructose metabolism and reverses MASH in human liver slices and murine models in vivo.
Cannabinoid Receptor 2 Activating Antibodies: A Promising Therapeutic Strategy for Macrophage-Driven Fibro-Inflammatory Diseases
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD).
Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions.
Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatohepatitis
Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatohepatitis.
Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome.
Targeting CCL24 in Inflammatory and Fibrotic Diseases: Rationale and Results from Three CM-101 Phase 1 Studies
Author Correction: Senolytic CAR T cells reverse senescence-associated pathologies
Author Correction: Senolytic CAR T cells reverse senescence-associated pathologies.
Stellate cell-specific adhesion molecule protocadherin 7 regulates sinusoidal contraction.
Kisspeptin Alleviates Human Hepatic Fibrogenesis by Inhibiting TGFβ Signaling in Hepatic Stellate Cells.
Mannose Supplementation Curbs Liver Steatosis and Fibrosis in Murine MASH by Inhibiting Fructose Metabolism
Swept up in the tsunami: Pediatric and adolescent steatotic (fatty) liver disease.
Kisspeptin Alleviates Human Hepatic Fibrogenesis by Inhibiting TGFb Signaling in Hepatic Stellate Cells